{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:00:49Z","timestamp":1774584049812,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cpet.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T19:07:10Z","timestamp":1622142430000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Theranostic Agents in Musculoskeletal Disorders"],"prefix":"10.1016","volume":"16","author":[{"given":"Sanaz","family":"Katal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Carrascoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Gholamrezanezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cpet.2020.06.008","article-title":"Potential applications of PET\/CT\/MR imaging in inflammatory diseases. Part I: musculoskeletal and gastrointestinal systems","volume":"15","author":"Katal","year":"2020","journal-title":"PET Clin"},{"key":"10.1016\/j.cpet.2021.03.008_bib3","article-title":"Non-oncologic Applications of PET\/CT and PET\/MR in Musculoskeletal, Orthopedic, and Rheumatologic Imaging: General Considerations, Techniques, and Radiopharmaceuticals","author":"Gholamrezanezhad","year":"2017","journal-title":"J\u00a0Nucl Med Technol"},{"key":"10.1016\/j.cpet.2021.03.008_bib4","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 Positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2021.03.008_bib5","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-12-1414","article-title":"Personalised nanomedicine","volume":"18","author":"Lammers","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.cpet.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.7150\/thno.40403","article-title":"PET imaging of liposomal glucocorticoids using 89Zr-oxine: theranostic applications in inflammatory arthritis","volume":"10","author":"Gawne","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2021.03.008_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2004.029751","article-title":"Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Haringman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.cpet.2021.03.008_bib8","first-page":"253","article-title":"Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan\u2122","volume":"27","author":"Matteson","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cpet.2021.03.008_bib9","first-page":"1435","article-title":"Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages","volume":"9","author":"HenneWA","year":"2012","journal-title":"MolPharm"},{"key":"10.1016\/j.cpet.2021.03.008_bib10","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/art.30363","article-title":"Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography\/computed tomography","volume":"63","author":"Piscaer","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.cpet.2021.03.008_bib11","first-page":"16N","article-title":"Future of nuclear medicine: SPECT versus PET","volume":"50","author":"Gholamrezanejhad","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s13346-018-0589-2","article-title":"The folate receptor \u03b2 as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis","volume":"15","author":"Chandrupatla","year":"2019","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.cpet.2021.03.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4191","article-title":"Evaluation of the novel folate receptor ligand [18 F] fluoro-PEG-folate for macrophage targeting in a rat model of arthritis","volume":"15","author":"Gent","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1325-x","article-title":"In-vivo monitoring of anti-folate therapy in arthritic rats using [18 F] fluoro-PEG-folate and positron emission tomography","volume":"19","author":"Chandrupatla","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cpet.2021.03.008_bib15","doi-asserted-by":"crossref","first-page":"8092781","DOI":"10.1155\/2018\/8092781","article-title":"Imaging and methotrexate response monitoring of systemic inflammation in arthritic rats employing the macrophage PET tracer [18F] fluoro-PEG-folate","volume":"2018","author":"Chandrupatla","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.cpet.2021.03.008_bib16","article-title":"Rheumatoid arthritis imaging on PET-CT using a novel folate receptor ligand for macrophage targeting","volume":"69","author":"Verweij","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.cpet.2021.03.008_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/acs.molpharmaceut.5b00989","article-title":"Synthesis and preclinical evaluation of folate-NOTA-Al18F for PET imaging of folate-receptor-positive tumors","volume":"13","author":"Chen","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cpet.2021.03.008_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00259-008-0987-7","article-title":"Quantification of (R)- [11C]PK11195 binding in rheumatoid arthritis","volume":"36","author":"Kropholler","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.cpet.2021.03.008_bib19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/rheumatology\/kew484","article-title":"Advances in positron emission tomography for the imaging of rheumatoid arthritis","volume":"56","author":"Narayan","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.cpet.2021.03.008_bib20","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1002\/art.23955","article-title":"Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography","volume":"58","author":"van der Laken","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.nano.2015.12.365","article-title":"Folate-targeted nanoparticles for rheumatoid arthritis therapy","volume":"12","author":"Nogueira","year":"2016","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.cpet.2021.03.008_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3304","article-title":"Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate","volume":"13","author":"Lu","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cpet.2021.03.008_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.nano.2018.01.009","article-title":"Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases","volume":"14","author":"Poh","year":"2018","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.cpet.2021.03.008_bib24","doi-asserted-by":"crossref","first-page":"W245","DOI":"10.2214\/AJR.17.18523","article-title":"Clinical nononcologic applications of PET\/CT and PET\/MRI in musculoskeletal, orthopedic, and rheumatologic imaging","volume":"210","author":"Gholamrezanezhad","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cpet.2021.03.008_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.24219","article-title":"Folate receptor \u03b2 as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients","volume":"60","author":"Van der Heijden","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpet.2021.03.008_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2008-04-150789","article-title":"A\u00a0functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages","volume":"113","author":"Xia","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cpet.2021.03.008_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cpet.2018.08.002","article-title":"Management of primary osseous spinal tumors with PET","volume":"14","author":"Batouli","year":"2019","journal-title":"PET Clin"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cpet.2018.05.012","article-title":"Applications of PET\/CT and PET\/MR imaging in primary bone malignancies","volume":"13","author":"Behzadi","year":"2018","journal-title":"PET Clin"},{"issue":"8","key":"10.1016\/j.cpet.2021.03.008_bib30","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.18632\/oncotarget.7063","article-title":"[68Ga] Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer: initial experience","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpet.2021.03.008_bib31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cpet.2021.03.008_bib32","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a 68Ga labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2021.03.008_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2021.03.008_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In\u00a0vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Philipp-Abbrederis","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cpet.2021.03.008_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A\u00a0review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2021.03.008_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/13543784.2012.656197","article-title":"Development of novel CXCR4-based therapeutics","volume":"21","author":"Peled","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.cpet.2021.03.008_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cbin.10631","article-title":"CXCR4 and CCR7: two eligible targets in targeted cancer therapy","volume":"40","author":"Mishan","year":"2016","journal-title":"Cell Biol Int"},{"issue":"10","key":"10.1016\/j.cpet.2021.03.008_bib38","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/ijms20102564","article-title":"What is the best radionuclide for immuno-PET of multiple myeloma? A comparison study between 89Zr-and 64Cu-labeled anti-CD138 in a preclinical syngeneic model","volume":"20","author":"Bailly","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.cpet.2021.03.008_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical development of CD38-targeted [89Zr] Zr-DFO-Daratumumab for imaging multiple myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib40","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1021\/acsnano.9b09618","article-title":"Osteotropic radiolabeled nanophotosensitizer for imaging and treating multiple myeloma","volume":"14","author":"Tang","year":"2020","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cpet.2018.05.011","article-title":"PET in the diagnostic management of soft tissue sarcomas of musculoskeletal origin","volume":"13","author":"Katal","year":"2018","journal-title":"PET Clin"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cpet.2020.06.001","article-title":"PET\/MR imaging in musculoskeletal precision imaging: third wave after X-ray and MR","volume":"15","author":"Hancin","year":"2020","journal-title":"PET Clin"},{"issue":"6","key":"10.1016\/j.cpet.2021.03.008_bib43","first-page":"3254","article-title":"Imaging of the muscle and bone from benchtop to bedside","volume":"24","author":"wang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"22","key":"10.1016\/j.cpet.2021.03.008_bib44","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1158\/1078-0432.CCR-08-0499","article-title":"Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma","volume":"14","author":"Rouleau","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bjc.2016.214","article-title":"Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells","volume":"115","author":"Thway","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/cbt.27825","article-title":"Antibody-based tumor vascular theranostics targeting endosialin\/TEM1 in a new mouse tumor vascular model","volume":"15","author":"Li","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.cpet.2021.03.008_bib47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2967\/jnumed.113.121905","article-title":"Development of 124I immuno-PET targeting tumor vascular TEM1\/endosialin","volume":"55","author":"Chacko","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2021.03.008_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2017.10.035","article-title":"Tumour endothelial marker 1\/endosialin-mediated targeting of human sarcoma","volume":"90","author":"Guo","year":"2018","journal-title":"Eur J Cancer"},{"issue":"36","key":"10.1016\/j.cpet.2021.03.008_bib49","doi-asserted-by":"crossref","first-page":"60368","DOI":"10.18632\/oncotarget.19499","article-title":"Generation of a novel antibody-drug conjugate targeting endosialin: potent and durable antitumor response in sarcoma","volume":"8","author":"Capone","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13550-020-00685-3","article-title":"177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma","volume":"10","author":"Delage","year":"2020","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.cpet.2021.03.008_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11307-020-01479-8","article-title":"Preclinical evaluation and dosimetry of [111In] CHX-DTPA-scFv78-Fc targeting endosialin\/tumor endothelial marker 1 (TEM1) [published correction appears in Mol Imaging Biol]","volume":"22","author":"Cicone","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.cpet.2021.03.008_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.cpet.2021.03.008_bib53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/cncr.26339","article-title":"Cell surface receptor expression patterns in osteosarcoma","volume":"118","author":"Hassan","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.cpet.2021.03.008_bib54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.nucmedbio.2016.07.008","article-title":"Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)","volume":"43","author":"Geller","year":"2016","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.cpet.2021.03.008_bib55","doi-asserted-by":"crossref","first-page":"9121","DOI":"10.1007\/s13277-016-4810-y","article-title":"Evaluation of (188) Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts","volume":"37","author":"Ma","year":"2016","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/j.cpet.2021.03.008_bib56","first-page":"170","article-title":"Theranostics of osteosarcoma and lung metastasis with new integrin \u03b1 v \u03b2 3 receptor targeted radiotracers","volume":"33","author":"Sui","year":"2019"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40658-016-0172-1","article-title":"3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma","volume":"4","author":"Sarrut","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"7","key":"10.1016\/j.cpet.2021.03.008_bib58","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/cas.13636","article-title":"\u03b1-Particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.cpet.2021.03.008_bib59","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2967\/jnumed.118.225409","article-title":"Preclinical pharmacokinetics and dosimetry studies of 124I\/131I-CLR1404 for treatment of pediatric solid tumors in murine xenograft models","volume":"60","author":"Marsh","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"5 Pt 1","key":"10.1016\/j.cpet.2021.03.008_bib60","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1203\/00006450-199905010-00016","article-title":"High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy","volume":"45","author":"Fr\u00fchwald","year":"1999","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.cpet.2021.03.008_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000012074","article-title":"Scintigraphic imaging of sarcomatous tumors with [111In-DTPA-Phe-1]-octreotide","volume":"58","author":"Giannakenas","year":"2000","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.cpet.2021.03.008_bib62","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/RLU.0000000000001288","article-title":"A\u00a0patient with metastatic sarcoma was successfully treated with radiolabeled somatostatin analogs","volume":"41","author":"Crespo-Jara","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2021.03.008_bib63","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1621::AID-CNCR33>3.0.CO;2-M","article-title":"Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma","volume":"86","author":"Friedberg","year":"1999","journal-title":"Cancer"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859821000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859821000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:09:22Z","timestamp":1761563362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859821000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1556859821000225"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2021.03.008","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostic Agents in Musculoskeletal Disorders","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}